Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- Biological: TUTI-16 (1.0 mg)Other: Placebo
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Thymon, LLC
- Target Recruit Count
- 27
- Registration Number
- NCT01335191
- Locations
- 🇺🇸
Clinilabs, New York, New York, United States
Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- Biological: TUTI-16 (0.2mg)Biological: TUTI-16 (1.0 mg)
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Thymon, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT01144026
- Locations
- 🇺🇸
Clinilabs, New York, New York, United States
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- Other: PlaceboBiological: TUTI-16 (0.03mg)Biological: TUTI-16 (0.1mg)Biological: TUTI-16 (0.6mg)
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Thymon, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00848211
- Locations
- 🇺🇸
Conant Medical Clinical Research, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath